Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose LEO 158968 study in subjects with gout flares
NL-OMON60008Phase 1Completed
- Sponsor
- LEO Pharma
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, single-arm trial of LEO 158968 in gout, sponsored by LEO Pharma. Primary endpoint: Primary endpoint(s). Started Aug 2024; status: completed.
02
Drugs
LEO 158968
03
Conditions
gout
Beyond the preview
Go deeper on NL-OMON60008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60008.